Finch Therapeutics Group, Inc.
NASDAQ: FNCH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Pink Sheets LLC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark Smith
- Employees
- 14
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $14.0M
- Website
- https://finchtherapeutics.com
Loading FNCH…
Loading profile data…Frequently asked questions about FNCH
What does Finch Therapeutics Group, Inc. (FNCH) do?
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, d...
Where does FNCH trade?
Finch Therapeutics Group, Inc. (FNCH) trades on the Pink Sheets LLC.
What sector is FNCH in?
Finch Therapeutics Group, Inc. (FNCH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Finch Therapeutics Group, Inc.?
Mark Smith is the chief executive officer of Finch Therapeutics Group, Inc. (FNCH).
Where is Finch Therapeutics Group, Inc. headquartered?
Finch Therapeutics Group, Inc. is headquartered in United States.
Does FNCH pay a dividend?
Finch Therapeutics Group, Inc. (FNCH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FNCH go public?
Finch Therapeutics Group, Inc. (FNCH) completed its initial public offering in 2021.